These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 18828848)

  • 1. A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.
    Langan SM; Williams HC
    Clin Exp Dermatol; 2009 Jan; 34(1):20-5. PubMed ID: 18828848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy of topical bufexamac in epidermolysis bullosa simplex. A double-blind placebo-controlled crossover trial.
    Fine JD; Johnson L
    Arch Dermatol; 1988 Nov; 124(11):1669-72. PubMed ID: 3178249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C4EB study-Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study.
    Schräder NHB; Duipmans JC; Renken RJ; Sörös P; Vermeulen KM; Bolling MC; Wolff AP
    PLoS One; 2022; 17(12):e0277512. PubMed ID: 36508401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.
    Chiaverini C; Roger C; Fontas E; Bourrat E; Bourdon-Lanoy E; Labrèze C; Mazereeuw J; Vabres P; Bodemer C; Lacour JP
    Orphanet J Rare Dis; 2016 Mar; 11():31. PubMed ID: 27015660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).
    Paller AS; Browning J; Nikolic M; Bodemer C; Murrell DF; Lenon W; Krusinska E; Reha A; Lagast H; Barth JA;
    Orphanet J Rare Dis; 2020 Jun; 15(1):158. PubMed ID: 32576219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.
    Kern JS; Schwieger-Briel A; Löwe S; Sumeray M; Davis C; Martinez AE
    Trials; 2019 Jun; 20(1):350. PubMed ID: 31186047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group.
    Caldwell-Brown D; Stern RS; Lin AN; Carter DM
    N Engl J Med; 1992 Jul; 327(3):163-7. PubMed ID: 1608407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial.
    Wally V; Hovnanian A; Ly J; Buckova H; Brunner V; Lettner T; Ablinger M; Felder TK; Hofbauer P; Wolkersdorfer M; Lagler FB; Hitzl W; Laimer M; Kitzmüller S; Diem A; Bauer JW
    J Am Acad Dermatol; 2018 May; 78(5):892-901.e7. PubMed ID: 29410318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum chloride hexahydrate and blistering in epidermolysis bullosa simplex.
    Younger IR; Priestley GC; Tidman MJ
    J Am Acad Dermatol; 1990 Nov; 23(5 Pt 1):930-1. PubMed ID: 2254479
    [No Abstract]   [Full Text] [Related]  

  • 11. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study.
    Murrell DF; Paller AS; Bodemer C; Browning J; Nikolic M; Barth JA; Lagast H; Krusinska E; Reha A;
    Orphanet J Rare Dis; 2020 Jul; 15(1):190. PubMed ID: 32693833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical gabapentin 10% in the treatment of epidermolysis bullosa pruritus: A pilot, double-blind, split-site, randomized controlled trial.
    Saki N; Vahedi S; Parvizi MM; Shafie'ei M; Hosseini SA; Ahramiyanpour N
    Dermatol Ther; 2022 Oct; 35(10):e15767. PubMed ID: 36117146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of epidermolysis bullosa simplex (EBS) with tetracycline.
    Veien NK; Buus SK
    Arch Dermatol; 2000 Mar; 136(3):424-5. PubMed ID: 10724216
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis.
    Pabón-Carrasco M; Caceres-Matos R; Roche-Campos M; Hurtado-Guapo MA; Ortiz-Romero M; Gordillo-Fernández LM; Pabón-Carrasco D; Castro-Méndez A
    Healthcare (Basel); 2024 Jan; 12(2):. PubMed ID: 38275540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa.
    Garcia-Doval I; Davila-Seijo P; Langan SM
    Clin Exp Dermatol; 2013 Jan; 38(1):92-4. PubMed ID: 22731863
    [No Abstract]   [Full Text] [Related]  

  • 16. A Case of Dystrophic Epidermolysis Bullosa Responding to Oral Corticosteroids.
    De A; Rao S; Dixit A; Basu K
    Indian J Dermatol; 2024; 69(2):182-184. PubMed ID: 38841237
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of systematic reviews on the treatment of vesiculobullous skin diseases. A meta-epidemiological study.
    Sá KMM; Rodrigues JC; da Silva LB; Santos GM; Colovati MES; Martimbianco ALC
    An Bras Dermatol; 2024; 99(2):223-232. PubMed ID: 37985301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa.
    Hasan SB; Gendra R; James J; Morris D; Orenstein LAV; Ingram JR
    Br J Dermatol; 2022 Dec; 187(6):846-854. PubMed ID: 35962565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review.
    Martina E; Diotallevi F; Radi G; Campanati A; Offidani A
    Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33562846
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.